Results of systemic therapy and evaluation of prognostic factors in patients with late progression of renal cell carcinoma

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Late progression of renal cell carcinoma (RCC) after radical nephrectomy is not uncommon, but data on systemic therapy response are limited.

Aim. To analyze survival rates and responses to systemic therapy, and to identify prognostic factors in RCC patients with late progression after radical nephrectomy.

Materials and methods. A retrospective analysis of data of 161 patients treated at the Municipal Oncologic Hospital No. 62 in Moscow and the Municipal Oncologic Dispensary in Saint Petersburg between 2006 and 2022 was performed. Mean patient age was 63.3 years (40–77 years), 68.1 % were men, all patients had previously undergone radical nephrectomy. 77 % of patients had a favorable prognosis and 18 % had an intermediate prognosis according to IMDC (International Metastatic RCC Database Consortium). We analyzed clinical and morphological data of patients who received systemic therapy for RCC diagnosed more than 5 years after radical nephrectomy. Statistical analysis was performed using Statistica 10.0 software packages (StatSoft, USA) by constructing Kaplan–Meier curves and survival tables, building a mathematical model of survival.

Results and conclusion. Median overall survival (OS) in the overall patient cohort was 52.3 months (confidence interval (CI) 43.8–62.9), and 3-year and 5-year OS were 64 % (95 % CI 57–72) and 43 % (95 % CI 36–52). All patients received first-line targeted therapy: tyrosine kinase inhibitor therapy was administered to 159 (98.7 %) and mTOR inhibitor therapy to 2 (1.3 %) patients, respectively. Median duration of first-line therapy was 34.1 months; 124 (77 %) patients received second-line therapy.

Univariate analysis in patients with late RCC progression showed that histologic variant (p = 0.048) and degree of tumor differentiation (p = 0.005), number of metastases (p = 0.003), metastases to lymph nodes (p = 0.026) and performance of metastasectomy (p = 0.028) were additional factors independently affecting OS rates.

Multivariate analysis showed that histological variant (p = 0.048) and degree of tumor differentiation (p = 0.045), IMDC prognosis (p = 0.005), bone metastases (p = 0.039), brain metastases (p < 0.001) and metastasectomy (p = 0.001) were additional factors with an independent effect on OS in patients with late RCC progression.

Patients with late RCC progression have higher OS and treatment response rates with systemic therapy due to a number of favorable prognostic characteristics.

About the authors

Dmitry V. Semenov

Saint Petersburg State University; City Clinical Oncology Dispensary, Saint Petersburg

Author for correspondence.
Email: sema.69@mail.ru
Russian Federation, 7/9 Universitetskaya Naberezhnaya, Saint Petersburg 199034; 56 Prospekt Veteranov, Saint Petersburg 198255

R. V. Orlova

Saint Petersburg State University; City Clinical Oncology Dispensary, Saint Petersburg

Email: sema.69@mail.ru
ORCID iD: 0000-0002-9368-5517
Russian Federation, 7/9 Universitetskaya Naberezhnaya, Saint Petersburg 199034; 56 Prospekt Veteranov, Saint Petersburg 198255

V. I. Shirokorad

Moscow City Oncological Hospital No. 62, Moscow Healthcare Department

Email: sema.69@mail.ru
ORCID iD: 0000-0002-8460-4463
Russian Federation, 27 Istra, Moscow Region 143523, Russia

S. V. Kostritskiy

Moscow City Oncological Hospital No. 62, Moscow Healthcare Department

Email: sema.69@mail.ru
ORCID iD: 0000-0003-4494-1489
Russian Federation, 27 Istra, Moscow Region 143523, Russia

References

  1. Capitanio U., Bensalah K., Bex A. et al. Epidemiology of renal cell carcinoma. Eur Urol 2019;75(1):74–84. doi: 10.1016/j.eururo.2018.08.036
  2. Leibovich B.C., Blute M.L., Cheville J.C. et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97(7):1663–71. doi: 10.1002/cncr.11234
  3. Park Y.H., Baik K.D., Lee Y.J. et al. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis. BJU Int 2012;110(11 Pt B):E553–58. doi: 10.1111/j.1464-410x.2012.11246.x
  4. Brookman-May S., May M., Shariat S.F. et al. Members of the CORONA project and the SATURN project. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Eur Urol 2013;64(3):472–7. doi: 10.1016/j.eururo.2012.06.030
  5. Kroeger N., Choueiri T.K., Lee J.L. et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol 2014;65(6): 1086–92. DOI: 0.1016/j.eururo.2013.07.031
  6. Adamy A., Chong K.T., Chade D. et al. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 2011;185(2):433–8. doi: 10.1016/j.juro.2010.09.100
  7. Heng D.Y., Xie W., Regan M.M. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013;14(2):141–8. doi: 10.1016/S1470-2045(12)70559-4
  8. Santoni M., Conti A., Porta C. et al. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. J Urol 2015;193(1):41–7. doi: 10.1016/j.juro.2014.07.011
  9. Grassi P., Verzoni E., Mariani L. et al. Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. Clin Genitourin Cancer 2013;11(4):484–8. doi: 10.1016/j.clgc.2013.04.022
  10. Kalra S., Atkinson B.J., Matrana M.R. et al. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int 2016;117(5):761–5. doi: 10.1111/bju.13185
  11. McKay R.R., Kroeger N., Xie W. et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 2014;65(3):577–84. doi: 10.1016/j.eururo.2013.08.012
  12. Valenca L.B., Hirsch M.S., Choueiri T.K., Harshman L.C. Non-clear cell renal cell carcinoma, part 2: therapy. Clin Adv Hematol Oncol 2015;13(6):383–91.
  13. Kroeger N., Xie W., Lee J.L. et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013;119(16):2999–3006. doi: 10.1002/cncr.28151
  14. Heng D.Y., Xie W., Regan M.M. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27(34):5794–9. doi: 10.1200/JCO.2008.21.4809
  15. Motzer R.J., Hutson T.E., Cella D. et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722–31. doi: 10.1056/NEJMoa1303989
  16. Santoni M., Buti S., Conti A. et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol 2015;10(4):517–22. doi: 10.1007/s11523-014-0356-3

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

License URL: https://oncourology.abvpress.ru/oncur/about/editorialPolicies
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.